Approximately 5%–10% of breast cancer (BC) patients carry germline mutations in BRCA1 or BRCA2 genes (gBRCA1/2m), tumor suppressor genes that synthetise proteins that are essential for the recognition and subsequent high-fidelity repair of DNA double-strand breaks by homologous recombination repair machinery (HRR) [1]. This evidence concerns the gene BRCA2 and breast carcinoma.